major depressive disorder
Coverage of major depressive disorder in the Nexus archive.
- Common gym supplement could help fight depression, new research suggests
A systematic review suggests creatine monohydrate may help improve depression symptoms when used as an add-on treatment, though results from five trials were mixed. Some studies showed benefits in depression and cognitive behavioral therapy, while others found no significant improvements, particularly in bipolar depression and teen populations. Researchers emphasize the evidence is preliminary and further exploration is needed.
- LSD's Depression Win; Summer Heat and Suicide; Antipsychotic Nonresponse Predictors
A phase III trial of an investigational LSD-based pill (DT120) showed it met primary and key secondary endpoints in treating adults with major depressive disorder, according to Definium Therapeutics. The results suggest potential efficacy for the treatment of depression.
- Guts may hold the key to happiness
New research on mouse gut microbiomes suggests GLP-1 drugs like Ozempic may reduce depression and anxiety symptoms by altering gut bacteria, specifically increasing Lactobacillus delbrueckii, which produces stress-calming compounds. The study highlights a brain-gut connection linking these diabetes/weight-loss drugs to mood regulation.
- Trivia Nights, Valentine’s Cards: Overlooked Social Connections Can Prevent Suicide
The article highlights how social connections, such as community activities, can prevent suicide, as emphasized by Steve Siple, who has experienced suicidal thoughts and lost family members to suicide. Research shows loneliness is a significant risk factor, leading to increased suicide rates, particularly among older adults and youths. Advocates are pushing for public policy solutions to address social isolation as part of suicide prevention efforts.
- Single infusion of controversial drug changed severe depression symptoms within hours, study finds
A study reviewed 26 clinical trials involving over 1,100 patients, finding that a single ketamine infusion significantly reduced severe depression symptoms within four hours and lowered suicidal thoughts within 24 hours. The analysis suggests ketamine may offer rapid relief for treatment-resistant depression, though it carries risks like dissociation and nausea.
- FDA moves to fast-track review of 3 psychedelic drug studies
The FDA granted fast-track review to three companies studying psychedelic therapies for depression and PTSD, with two focusing on psilocybin for treatment-resistant depression and major depressive disorder. This move aligns with the Trump administration's push for potential approval of psychedelic treatments.